Table 4.
Results of the unadjusted and multivariable cause-specific, time-dependent Cox models studying the risk of squamous cell carcinoma (n=2416)
| Exposure | Unadjusted | Adjusted | ||
|---|---|---|---|---|
| Hazard Ratio | 95% Confidence Interval | Hazard Ratio | 95% Confidence Interval | |
| HTCZ exposure | 2.36 | [1.53 to 3.65] | 2.04 | [1.27 to 3.28] |
| Recipient age | 1.07 | [1.05 to 1.08] | 1.06 | [1.04 to 1.07] |
| Men | 2.10 | [1.40 to 3.13] | 2.22 | [1.45 to 3.39] |
| Initial nephropathy | ||||
| Chronic tubulointerstitial nephritis/ADPKD/congenital uropathy (versus glomerulopathy) | 0.75 | [0.49 to 1.16] | 0.86 | [0.56 to 1.33] |
| Diabetes (versus glomerulopathy) | 0.53 | [0.29 to 0.97] | 0.61 | [0.26 to 1.40] |
| Other (versus glomerulopathy) | 1.43 | [0.83 to 2.46] | 1.01 | [0.53 to 1.90] |
| Vascular nephropathy (versus glomerulopathy) | 1.62 | [0.88 to 2.99] | 0.73 | [0.38 to 1.42] |
| KRT | — | — | ||
| Hemodialysis (versus preemptive transplantation) | 1.54 | [0.91 to 2.61] | — | — |
| Peritoneal dialysis (versus preemptive transplantation) | 1.42 | [0.63 to 3.23] | — | — |
| Kidney transplantation | 2.49 | [1.22 to 5.06] | 0.68 | [0.19 to 2.36] |
| Retransplantation | 1.99 | [1.36 to 2.90] | 2.41 | [1.16 to 4.99] |
| Deceased donor | 2.79 | [1.23 to 6.34] | 1.65 | [0.67 to 4.05] |
| HLA-A -B -Dr mismatches ≥4 | 0.90 | [0.64 to 1.26] | 0.96 | [0.65 to 1.40] |
| Cold ischemia time ≥18 h | 1.60 | [1.13 to 2.29] | 1.32 | [0.88 to 1.98] |
| Delayed graft function | 1.49 | [1.05 to 2.11] | 0.96 | [0.66 to 1.40] |
| Rejection | 0.17 | [0.04 to 0.71] | 0.24 | [0.06 to 1.01] |
| Other malignancies | 0.56 | [0.17 to 1.81] | 0.19 | [0.05 to 0.66] |
| Induction treatment | ||||
| Nondepleting (versus depleting) | 1.04 | [0.74 to 1.48] | 1.19 | [0.61 to 2.35] |
| None (versus depleting) | 0.77 | [0.28 to 2.12] | 0.97 | [0.30 to 3.18] |
| Calcineurin inhibitors | ||||
| Cyclosporin (versus tacrolimus) | 0.48 | [0.29 to 0.80] | 0.67 | [0.39 to 1.16] |
| None (versus tacrolimus) | 0.32 | [0.04 to 2.42] | 0.25 | [0.03 to 1.90] |
| Steroid-free regimen | 0.96 | [0.64 to 1.43] | 1.05 | [0.66 to 1.68] |
| Calcineurin inhibitors during follow-up | 0.39 | [0.26 to 0.59] | 0.29 | [0.16 to 0.52] |
| mTOR inhibitors during follow-up | 0.93 | [0.49 to 1.76] | 0.30 | [0.13 to 0.68] |
| Mycophenolate derivatives during follow-up | 0.47 | [0.32 to 0.70] | 0.64 | [0.41 to 1.01] |
HCTZ, hydrochlorothiazide; ADPKD, autosomal dominant polycystic kidney disease; —, not available; HLA, human leucocyte antigen; mTOR, mammalian target of rapamycin.